Tamara-Castaño-Bonilla

Tamara Castaño Bonilla

Specialty:
Hematology and hemotherapy
Serving specialties:
  • Hematology and Hemotherapy
Hospitals where he/she works:
  • Hospital Universitario Fundación Jiménez Díaz
General Information
Experience

2020–Present: Consultant in Hematology. Flow Cytometry Laboratory and Outpatient Clinics. Fundación Jiménez Díaz

2019–2020: Consultant in Hematology. Molecular Biology Laboratory / Fundación Jiménez Díaz

2019: Consultant in Hematology. Outpatient Clinics and Cytomorphology Laboratory / Hospital Universitario Puerta de Hierro

2018: Consultant in Hematology. Outpatient Clinics and Inpatient Ward / Fundación Jiménez Díaz

2018: Consultant in Hematology. Outpatient Clinics and Inpatient Ward / Hospital Universitario Rey Juan Carlos

2018: Consultant in Hematology. Cytogenetics and Molecular Biology Laboratory / Fundación Jiménez Díaz

2014–2018: Resident in Hematology and Hemotherapy / Fundación Jiménez Díaz

Degree

Bachelor of Medicine and Surgery, Autonomous University of Madrid (2013)

Specialist in Hematology and Hemotherapy (2014–2018)

Techniques

PCR, qPCR, and NGS (molecular biology) and hematologic flow cytometry studies (screening for B and T CLPD, MM and myeloid disorders (MPN, MDS/acute leukemias...), MRD monitoring in MM, acute leukemias, and CLPD, PNH screening, CD34+ cell count, glycoprotein studies, platelet activation and secretion, fetal hemoglobin analysis...)

Research and teaching

Scientific-technical report. Consensus report on the diagnosis and follow-up of AML and ALL by the Spanish Group of Hematologic Flow Cytometry (GECFH).

Doctoral Thesis: "Mesenchymal cells as a prognostic biomarker in patients diagnosed with acute myeloblastic leukemia".

Doctoral Thesis: "Importance of rs12459419 CD33 polymorphism for prediction of gemtuzumab ozogamicin response in consolidation treatment of acute myeloid leukemia patients: experience of PETHEMA group".

Doctoral Thesis: "Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens".

EPI-BLAS Project: Blastic plasmacytoid dendritic cell neoplasm.

Project: ATRA plus FLAG-IDA in Relapsed/Refractory Acute Myeloid Leukemia patients with MECOM rearrangements and/or EVI-1 overexpression. 27/02/2024–2028.

Teaching collaborator Universidad Autonoma de Madrid (UAM)


Publications

1. Spontaneous Remission of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. Medicina. doi: 10.3390/medicina60050807.

2. Therapeutics of acute myeloid leukemia with central nervous system involvement. Clin Hematol Int. doi: 10.46989/001c.131722.

3. Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage. Annals of Hematology. doi: 10.1007/s00277-024-05647-6.

4. No evidence that CD33 rs12459419 polymorphism predicts gemtuzumab ozogamicin response in consolidation treatment of acute myeloid leukemia patients: experience of the PETHEMA group. Disease Markers. 2022. doi: 10.1155/2022/3132941.

5. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. Scientific Reports. 11-20745. doi: 10.1038/s41598-021-00050-x

6. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients. Molecular Diagnosis & Therapy. 24, pp.593–600. doi: 10.1007/s40291-020-00485-4

7. Platelet Function and Bleeding Tendency in Patients under Ibrutinib Therapy. Annals of Hematology & Oncology. 4-(11): 1179.

8. When the devil is in the details: Similarities and differences between WHO and ICC classification of AML. Leukemia Research. doi: 10.1016/j.leukres.2024.107440.

9. Flow Cytometry analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome. eJHaem. In press. doi:10.1002/jha2.7005

Communications and Presentations

Oral communication: "Primary hemostasis alterations induced by ibrutinib. Bleeding side effects of the treatment". European Congress on Thrombosis and Haemostasis (ECTH). 2016. Netherlands.

Talk: "Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile". VI Meeting of the Hematologic Diagnosis by Flow Cytometry Group (DHC). 2017. Spain

Oral communication: "Flow Cytometry: measurement of peripheral blood expression/lymphocytes of cutaneous T lymphomas". XV Congress SIC 2017. Lisbon (Portugal)

Talk: "Chronic myeloid leukemia... with a twist". Clinical-cytological cases at the interannual meeting of the Spanish Hematologic Cytology Group. 2017. Spain

Oral communication: "Primary thrombotic microangiopathies. Review of the last 9 years at a single center". LIX National Congress of SEHH and XXXIII National Congress of SETH. 2017. Spain.

Talk: "Acute Myeloblastic Leukemia with thrombocytosis and t (3;3)". Lymphoma & Leukemia. Diagnosis for Targeted Therapy. 2017. Spain.

Oral communication: "Unclassifiable B-cell lymphoma with features of splenic marginal zone lymphoma and splenic red pulp lymphoma: Description of clonal evolution using cytogenetic and massive sequencing techniques". VII Symposium of the Spanish Cooperative Group on Hematologic Cytogenetics. 2018. Spain.

Talk: "Lights and shadows in early characterization of hematopoietic precursors", Lymphoma & Leukemia. Diagnosis for Targeted Therapy. 2021. Spain

Talk: Diagnostic and therapeutic update in AML: Detection of measurable residual disease in AML. 2023. Spain

Talk: "CLL and lymphomas workshop. Clinical cases B-CLPD". 2024. Spain

Awards and certifications

"CLL and invasive fungal infection". Winner of the 3rd prize for oral communication. Medical Education. VIII Course for Hematology and Hemotherapy Residents. Update on CLL and Lymphomas. Janssen-Cilag Spain. 2016. Spain.